SilverCrest Metals
SILV
Collegium Pharmaceutical
COLL
Cars.com
CARS
Hutchmed (China)
HCM
Halozyme Therapeutics
HALO
(Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 16.96%118.81M | 22.70%430.52M | 20.88%114.38M | 20.23%110.64M | 22.72%103.93M | 27.71%101.58M | 28.96%350.87M | 25.29%94.62M | 32.10%92.02M | 30.91%84.69M |
Operating revenue | 16.96%118.81M | 22.70%430.52M | 20.88%114.38M | 20.23%110.64M | 22.72%103.93M | 27.71%101.58M | 28.96%350.87M | 25.29%94.62M | 32.10%92.02M | 30.91%84.69M |
Cost of revenue | 1.14%31.93M | 10.94%123.66M | -0.37%30.74M | 7.34%30.58M | 14.87%30.77M | 24.63%31.57M | 12.49%111.46M | 13.62%30.85M | 9.58%28.49M | 13.72%26.79M |
Gross profit | 24.10%86.87M | 28.17%306.86M | 31.16%83.64M | 26.01%80.06M | 26.35%73.16M | 29.15%70M | 38.40%239.41M | 31.84%63.77M | 45.51%63.53M | 40.74%57.91M |
Operating expense | 12.10%94.13M | 10.42%339.05M | 9.35%83.34M | 7.00%87.5M | 8.45%84.25M | 17.60%83.97M | 12.71%307.07M | 7.04%76.21M | 13.02%81.78M | 18.70%77.68M |
Selling and administrative expenses | 11.23%61.7M | 5.72%225.42M | 5.50%53.5M | 6.53%60.19M | 3.64%56.27M | 7.25%55.47M | 7.67%213.22M | -1.66%50.71M | 8.79%56.5M | 12.97%54.29M |
-Selling and marketing expense | 9.71%37.76M | 4.53%138.18M | 2.59%33.23M | 0.89%35.26M | 5.16%35.27M | 9.92%34.42M | 18.13%132.19M | 5.65%32.39M | 21.51%34.95M | 24.96%33.54M |
-General and administrative expense | 13.71%23.94M | 7.67%87.24M | 10.65%20.27M | 15.67%24.93M | 1.17%21M | 3.15%21.05M | -5.92%81.03M | -12.38%18.32M | -7.00%21.55M | -2.19%20.75M |
Research and development costs | 13.79%32.43M | 21.08%113.63M | 17.02%29.84M | 8.06%27.32M | 19.62%27.98M | 44.80%28.5M | 26.12%93.85M | 29.89%25.5M | 23.77%25.28M | 34.55%23.39M |
Operating profit | 48.06%-7.25M | 52.42%-32.19M | 102.43%302K | 59.19%-7.45M | 43.96%-11.08M | 18.79%-13.97M | 31.97%-67.66M | 45.50%-12.44M | 36.42%-18.25M | 18.61%-19.78M |
Net non-operating interest income expense | 462.88%3.42M | 399.60%758K | -2,317.95%-943K | -548.72%-253K | ||||||
Non-operating interest income | ---- | ---- | ---- | --758K | ---- | ---- | ---- | ---- | ---- | ---- |
Non-operating interest expense | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 548.72%253K | ---- |
Total other finance cost | -462.88%-3.42M | ---- | ---- | ---- | ---- | --943K | ---- | ---- | ---- | ---- |
Other net income (expense) | 201.11%2.29M | 321.52%2.06M | 38.20%-2.26M | 54.17%-659K | 216.47%488K | |||||
Special income (charges) | ---- | --0 | --0 | --0 | --0 | ---- | 33.49%-1.6M | --0 | --0 | --348K |
-Less:Other special charges | ---- | ---- | ---- | ---- | ---- | ---- | -33.49%1.6M | --0 | ---- | ---348K |
Other non- operating income (expenses) | ---- | 446.74%2.29M | ---- | ---- | 1,369.29%2.06M | ---- | 47.28%-659K | ---- | ---- | 133.41%140K |
Income before tax | 74.30%-3.83M | 57.23%-29.91M | 105.83%715K | 63.84%-6.69M | 53.21%-9.03M | 24.97%-14.91M | 32.19%-69.92M | 48.96%-12.27M | 36.23%-18.5M | 22.09%-19.29M |
Income tax | 66.59%688K | 527.27%2.12M | 265.03%1.31M | 157.55%202K | -59.66%188K | 123.24%413K | 85.59%-495K | 67.48%-795K | -29.52%-351K | 187.76%466K |
Net income | 70.50%-4.52M | 53.88%-32.02M | 94.80%-597K | 62.03%-6.89M | 53.36%-9.21M | 23.60%-15.32M | 30.35%-69.43M | 46.87%-11.47M | 36.85%-18.15M | 18.46%-19.75M |
Net income continuous Operations | 70.50%-4.52M | 53.88%-32.02M | 94.80%-597K | 62.03%-6.89M | 53.36%-9.21M | 23.60%-15.32M | 30.35%-69.43M | 46.87%-11.47M | 36.85%-18.15M | 18.46%-19.75M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 70.50%-4.52M | 53.88%-32.02M | 94.80%-597K | 62.03%-6.89M | 53.36%-9.21M | 23.60%-15.32M | 30.35%-69.43M | 46.87%-11.47M | 36.85%-18.15M | 18.46%-19.75M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 70.50%-4.52M | 53.88%-32.02M | 94.80%-597K | 62.03%-6.89M | 53.36%-9.21M | 23.60%-15.32M | 30.35%-69.43M | 46.87%-11.47M | 36.85%-18.15M | 18.46%-19.75M |
Basic earnings per share | 72.73%-0.06 | 58.33%-0.45 | 94.12%-0.01 | 67.86%-0.09 | 58.06%-0.13 | 31.25%-0.22 | 33.74%-1.08 | 51.43%-0.17 | 40.43%-0.28 | 22.50%-0.31 |
Diluted earnings per share | 72.73%-0.06 | 58.33%-0.45 | 94.12%-0.01 | 67.86%-0.09 | 58.06%-0.13 | 31.25%-0.22 | 33.74%-1.08 | 51.43%-0.17 | 40.43%-0.28 | 22.50%-0.31 |
Dividend per share | ||||||||||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- |